[verwijderd] 24 oktober 2007 16:31 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 The 3rd annual European Antibody Congress 5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France Development of a human cell line based manufacturing platform Development of the PER.C6® based production platform for therapeutic proteinsThe PER.C6® manufacturing platform: scalability, speed to clinic and product quality Manufacturing vision and innovative concepts; the 10 g/L XD™ process Robert Hof, Program Manager Biomanufacturing, DSM Biologics Achieving higher productivity in antibody production - improved strategies for cell platform and cell culture engineeringAdvanced technology for cell line developmentOptimising cell culture media via high-throughput methods Jonathan Dempsey, Process Science Fellow, Invitrogen Antibody production timeframe shortening and technology transfeRapid and efficient cell cultivation process transfer and scale-up Production of clinical supplies of therapeutic antibodiesMichel Chartrain, Distinguished Senior Investigator, Bioprocess Research and Development, Merck Research LaboratoriesFast track production of large numbers of different IgG candidatesEngineering therapeutic antibodies with pre-defined characteristicsVarious strategies to provide antibody material in screening scale for initial functional and biophysical characterisationA fully scalable system for the production of gram amounts of IgG Armin Weidmann, Director of Research and Development, MorphoSys AG enzwww.terrapinn.com/2007/antibody/confp... Aanbevelingen 3 ” Quote Reageren Niet oké
[verwijderd] 28 oktober 2007 11:37 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 PERCIVIAWest Coast Per.C6 Technology Seminar-San Francisco 11:30 PM, Oct 30, 2007 -- 18:00 PM, Oct 30, 2007 West Coast Per.C6 Technology Seminar-San Diego 11:30 PM, Oct 31, 2007 - 6:00 PM, Oct 31, 2007 including the XD process, expressing monoclonal antibodies at over 10g/L. secure2.ersvp.com/register/flow/flow5...Conference: 30-31 October 2007 Day Two: Wednesday 31 October 2007 Modelling Techniques and Tools in Technology Transfer Victor Papavasileiou, INTELLIGEN Europe, The Netherlands and Sander Worst, Crucell, The Netherlands www.bio-production.com/page.cfm?pagei...16.30 Using process simulation and scheduling tools to optimize development and manufacturing of monoclonal antibodies and vaccines and facilitate technology transfer.5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...Dinsdag 13 november 2007 Q3 2007 December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID... Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 29 oktober 2007 21:13 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 PERCIVIAWest Coast Per.C6 Technology Seminar-San Francisco 11:30 PM, Oct 30, 2007 -- 18:00 PM, Oct 30, 2007 West Coast Per.C6 Technology Seminar-San Diego 11:30 PM, Oct 31, 2007 - 6:00 PM, Oct 31, 2007 including the XD process, expressing monoclonal antibodies at over 10g/L. secure2.ersvp.com/register/flow/flow5...Conference: 30-31 October 2007 Day Two: Wednesday 31 October 2007 Modelling Techniques and Tools in Technology Transfer Victor Papavasileiou, INTELLIGEN Europe, The Netherlands and Sander Worst, Crucell, The Netherlands www.bio-production.com/page.cfm?pagei...16.30 Using process simulation and scheduling tools to optimize development and manufacturing of monoclonal antibodies and vaccines and facilitate technology transfer.5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...Dinsdag 13 november 2007 Q3 2007 Mon 03 Dec 2007 - Thu 06 Dec 2007 Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®Taking a closer look at recent PER.C6 human cell line developmentsDr Fons UytdeHaag, Director Corporate ScientificAffairs, Crucell NV, The Netherlandswww.iir-events.com/IIR-conf/LifeScien... December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 31 oktober 2007 15:09 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...Dinsdag 13 november 2007 Q3 2007 Mon 03 Dec 2007 - Thu 06 Dec 2007 Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®Taking a closer look at recent PER.C6 human cell line developmentsDr Fons UytdeHaag, Director Corporate ScientificAffairs, Crucell NV, The Netherlandswww.iir-events.com/IIR-conf/LifeScien... December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlFriday, January 11Protein Production Conference 11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities. Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLCDue to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform. www.chi-peptalk.com/08_PPD_day2.aspMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID... Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 31 oktober 2007 15:51 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 "8 November 2007 PERCIVIA 1 jaar na opening"Nou, ik ben wel benieuwd. Ik snap niet hoe een bedrijfsonderdeel wat met zoveel tam tam is opgestart, zichzelf zo lang uit het nieuws heeft weten te houden. Aanbevelingen 1 ” Quote Reageren Niet oké
aossa 31 oktober 2007 16:18 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 23 mrt 2025 Aanbevelingen Ontvangen: 4053 Gegeven: 3339 Aantal posts: 17.622 quote:williedevil schreef:"8 November 2007 PERCIVIA 1 jaar na opening"Nou, ik ben wel benieuwd. Ik snap niet hoe een bedrijfsonderdeel wat met zoveel tam tam is opgestart, zichzelf zo lang uit het nieuws heeft weten te houden.Heu !Mogelijk lees jij enkel de Fabeltejskrant.Voor het betere (wereld)nieuws kan je terecht op:crucell.yourbb.nl/viewtopic.php?t=27&... Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 31 oktober 2007 18:07 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 @ Aossa,Fabeltjeskrant was na mijn tijd, misschien dat jij daar in gelooft.Je verwijst me naar het andere forum, dat ook ik voortdurend volg.Overigens grote waardering voor allen die daar posten met name flosz natuurlijk, maar er zijn er veel meer..Een verwijzing o.a. naar de brochure van Percivia.Mooi geschreven wollige taal, waar ik ook gedeeltelijk ben ingetuind. Je moet die folder eens kritisch lezen, een en al verwijzing naar wat kan gaan gebeuren en hoe goed het platform wel niet is. Waarom komen er dan geen aansprekende berichten als gevolg van al dat fenomenale op de website van percivia terecht.. ik geloof dat die site een keer is gemaakt en nooit meer aangepast behoudens een verwijzing naar een conferentie, zelfs de vacatures zijn al maanden hetzelfde, maar ja.... ook ik kan me vergissen, misschien zijn ze te druk met andere dingen.Daarom o.a. ben ik benieuwd wat ze op 8 nov. over Percivia te melden hebben, het kan namelijk best ook wel goed nieuws zijn... het komt er steeds toch maar weer op neer dat ze de communicatie bij Crucell niet goed in de hand hebben, dat kost vertrouwen.Ik zou het heel graag anders zien. Vanuit de opportunities die de wetenschappers en de techneuten bij Crucell hebben geschapen ben ik echter niet pessimistisch. Het is het gedrag van het MT waardoor ik kansen verloren zie gaan en daarmee aandeelhouderswaarde VOEL verdampen. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 31 oktober 2007 22:18 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...Dinsdag 13 november 2007 Q3 2007 November 30, 2007 in Bangkok, ThailandJoint International TropicalMedicine Meeting 2007 Data from the Phase I clinical trial in India, to assess safety andefficacy, will be reported.Mon 03 Dec 2007 - Thu 06 Dec 2007 Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®Taking a closer look at recent PER.C6 human cell line developmentsDr Fons UytdeHaag, Director Corporate ScientificAffairs, Crucell NV, The Netherlandswww.iir-events.com/IIR-conf/LifeScien... December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlFriday, January 11Protein Production Conference 11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities. Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLCDue to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform. www.chi-peptalk.com/08_PPD_day2.aspMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 1 november 2007 15:20 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...MONDAY, NOVEMBER 12, 2007 - 09:00-10:30 BIO-EUROPEFrom Target to Clinic – Reduce the Time to Your First Important Milestone Dr. Jelto Swaving, Manager Upstream Process Development, DSM BiologicsDr. Ronald Vogels, Director Protein Expression and Cell Biology, Crucell Holland BVwww.ebdgroup.com/bioeurope/ws_panels.htmDinsdag 13 november 2007 Q3 2007 November 30, 2007 in Bangkok, ThailandJoint International TropicalMedicine Meeting 2007 Data from the Phase I clinical trial in India, to assess safety andefficacy, will be reported.Mon 03 Dec 2007 - Thu 06 Dec 2007 Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®Taking a closer look at recent PER.C6 human cell line developmentsDr Fons UytdeHaag, Director Corporate ScientificAffairs, Crucell NV, The Netherlandswww.iir-events.com/IIR-conf/LifeScien... December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlFriday, January 11Protein Production Conference 11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities. Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLCDue to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform. www.chi-peptalk.com/08_PPD_day2.aspMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 4 november 2007 19:55 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...MONDAY, NOVEMBER 12, 2007 - 09:00-10:30 BIO-EUROPEFrom Target to Clinic – Reduce the Time to Your First Important Milestone Dr. Jelto Swaving, Manager Upstream Process Development, DSM BiologicsDr. Ronald Vogels, Director Protein Expression and Cell Biology, Crucell Holland BVwww.ebdgroup.com/bioeurope/ws_panels.htmDinsdag 13 november 2007 Q3 2007 November 30, 2007 in Bangkok, ThailandJoint International TropicalMedicine Meeting 2007 Data from the Phase I clinical trial in India, to assess safety andefficacy, will be reported.Mon 03 Dec 2007 - Thu 06 Dec 2007 Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®Taking a closer look at recent PER.C6 human cell line developmentsDr Fons UytdeHaag, Director Corporate ScientificAffairs, Crucell NV, The Netherlandswww.iir-events.com/IIR-conf/LifeScien... December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlFriday, January 11Protein Production Conference 11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities. Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLCDue to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform. www.chi-peptalk.com/08_PPD_day2.aspMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID...HIV Pathogenesis (X8)Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates FoundationSaturday, March 298:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses Dan H. Barouch, Beth Israel Deaconess Medical Center Novel Adenovirus Vectors Sunday, March 308:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?Jaap Goudsmit, Crucell Holland B.V. Flu, TBwww.keystonesymposia.org/Meetings/Vie... Aanbevelingen 0 ” Quote Reageren Niet oké
gogogoo 4 november 2007 20:40 auteur info gogogoo Lid sinds: 28 feb 2006 Laatste bezoek: 10 aug 2023 Aanbevelingen Ontvangen: 1600 Gegeven: 808 Aantal posts: 6.042 Ook via flosz:World vaccine Congress 2008 21 – 24 April, 2008 The golden age of vaccines! World Vaccine Congress joins the 100 club World Vaccine Congress Washington 2008 is the largest, most established and most dynamic vaccine industry conference in North America. In 2008 the World Vaccines Congress Washington will be an even BIGGER event than any previously ran. This congress will put you face-to-face with over 100 of the World’s most compelling and influential scientific and business leaders in vaccines. It is the only programme in North America to successfully bring their renowned perspectives on vaccine market dynamics to the senior executive community. Officially it is the largest four day event in the vaccine industry calendar. The World Vaccine Congress Washington is an event like no other! Don`t just take our word for it, check out the 2008 speaker profile. Now held in conjunction with the Vaccine Industry Excellence Awards! And this year's congress will be even bigger The World Vaccine Congress Washington 2008 offers a unique opportunity to get a complete and up to date picture on developments within the North America vaccine industry. The premium fees and content qualify World Vaccine Congress Washington 2008 delegates as the highest value buyers and decision makers in the market. Unlike many conferences and showcases, The World Vaccine Congress Washington 2008 benefits from a high level, case-study driven conference programme, featuring senior executives from the region’s major vaccine developers – your customers and prospects. One of the many great features of The World Vaccine Congress Washington 2008 is that its content is packaged to attract your target market. The conference is designed with premium content aimed at providing the latest information and ideas to all the key target audiences. Our 2008 event Bigger certainly is better when it comes to the World Vaccine Congress Washington 2008. At this years 8th annual congress, the emphasis is very much on delivering the World’s most comprehensive and senior level vaccine conference. Showcasing over 100 speakers within 65 individual plenary and panel sessions, this 4 day event brings the industry’s foremost CxO level vaccine representatives face-to-face with the world’s most progressive advocates and practitioners of global vaccine health. World Vaccine Congress Washington 2008 is a conference of enormous magnitude and global significance. It deserves your attention and your attendance in April 2008. And this year's hot topic The 2008 World Vaccine Congress Washington is where the industry’s key stakeholders are meeting to analyse their scientific, strategic and tactical vaccine development strategies. Over the course of the 4 day conference you will have the opportunity to attend a total of 13 structured sessions, all pertinent to furthering your own knowledge, expertise and credentials. The event is geared to provide a dual role experience, one that delivers succinct learning whilst allowing you to engage in a global networking forum. Whether your interest lies in the vaccine investment climate, emerging global health initiatives, expanding market opportunities, R&D portfolio diversity, seasonal and pandemic preparedness, novel adjuvant and delivery technologies, vaccine safety evaluation, next generation vaccines, manufacturing strategy and technology or vaccine SME growth strategies, World Vaccine Congress Washington 2008 brings you closer to the action. Gold sponsor It is Crucell’s goal to improve healthcare throughout the world by fighting infectious diseases. Crucell does this by discovering, researching and developing technologies, vaccines and antibodies, using its own fully integrated infrastructure for in-house development, production and marketing and, where useful or necessary, by establishing partnerships with other companies and organizations. Headquartered in Leiden, The Netherlands, Crucell currently employs about 1100 people and has subsidiaries in Switzerland, Spain, Sweden, Italy and Korea. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health. www.terrapinn.com/2008/wvc_DC/index.stmcrucell.yourbb.nl/viewtopic.php?t=11&... Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 5 november 2007 08:17 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...MONDAY, NOVEMBER 12, 2007 - 09:00-10:30 BIO-EUROPEFrom Target to Clinic – Reduce the Time to Your First Important Milestone Dr. Jelto Swaving, Manager Upstream Process Development, DSM BiologicsDr. Ronald Vogels, Director Protein Expression and Cell Biology, Crucell Holland BVwww.ebdgroup.com/bioeurope/ws_panels.htmDinsdag 13 november 2007 Q3 2007 November 30, 2007 in Bangkok, ThailandJoint International TropicalMedicine Meeting 2007 Data from the Phase I clinical trial in India, to assess safety andefficacy, will be reported.Mon 03 Dec 2007 - Thu 06 Dec 2007 Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®Taking a closer look at recent PER.C6 human cell line developmentsDr Fons UytdeHaag, Director Corporate ScientificAffairs, Crucell NV, The Netherlandswww.iir-events.com/IIR-conf/LifeScien... December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlFriday, January 11Protein Production Conference 11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities. Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLCDue to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform. www.chi-peptalk.com/08_PPD_day2.aspMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID...HIV Pathogenesis (X8)Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates FoundationSaturday, March 298:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses Dan H. Barouch, Beth Israel Deaconess Medical Center Novel Adenovirus Vectors Sunday, March 308:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?Jaap Goudsmit, Crucell Holland B.V. Flu, TBwww.keystonesymposia.org/Meetings/Vie... 21 – 24 April, 2008 World vaccine Congress 2008 Gold sponsor Crucell (zie draadje) www.terrapinn.com/2008/wvc_DC/index.stmcrucell.yourbb.nl/viewtopic.php?t=11&... Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 5 november 2007 23:00 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje) The 3rd annual European Antibody Congress 8 November 2007 PERCIVIA 1 jaar na opening.Friday, 9 November 2007 09:00 – 17:00 38th Union World Conference on Lung Health Cape Town, South Africa www.worldlunghealth.org/Conf2007/webs...MONDAY, NOVEMBER 12, 2007 - 09:00-10:30 BIO-EUROPEFrom Target to Clinic – Reduce the Time to Your First Important Milestone Dr. Jelto Swaving, Manager Upstream Process Development, DSM BiologicsDr. Ronald Vogels, Director Protein Expression and Cell Biology, Crucell Holland BVwww.ebdgroup.com/bioeurope/ws_panels.htmDinsdag 13 november 2007 Q3 2007 28-11-2007Crucell Company visitNovember 30, 2007 in Bangkok, ThailandJoint International TropicalMedicine Meeting 2007 Data from the Phase I clinical trial in India, to assess safety andefficacy, will be reported.Mon 03 Dec 2007 - Thu 06 Dec 2007 Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®Taking a closer look at recent PER.C6 human cell line developmentsDr Fons UytdeHaag, Director Corporate ScientificAffairs, Crucell NV, The Netherlandswww.iir-events.com/IIR-conf/LifeScien... December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates 9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments Abstract to come. Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands www.ibclifesciences.com/D4173/8074.xmlFriday, January 11Protein Production Conference 11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities. Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLCDue to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform. www.chi-peptalk.com/08_PPD_day2.aspMonday ‐ January 28, 2008 16.30 – 17.00 ‘Ebola vaccination’Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.www.ewi.med.uu.nl/CTID/Programme_CTID...12-02-2008Crucell Jaarcijfers 2007 (voorbeurs)HIV Pathogenesis (X8)Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates FoundationSaturday, March 298:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses Dan H. Barouch, Beth Israel Deaconess Medical Center Novel Adenovirus Vectors Sunday, March 308:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?Jaap Goudsmit, Crucell Holland B.V. Flu, TBwww.keystonesymposia.org/Meetings/Vie... 21 – 24 April, 2008 World vaccine Congress 2008 Gold sponsor Crucell (zie draadje) www.terrapinn.com/2008/wvc_DC/index.stmcrucell.yourbb.nl/viewtopic.php?t=11&... Aanbevelingen 0 ” Quote Reageren Niet oké
aossa 7 november 2007 15:23 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 23 mrt 2025 Aanbevelingen Ontvangen: 4053 Gegeven: 3339 Aantal posts: 17.622 Hier zitten ze dus MT en IREuropean Antibody Congres 20075 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France Congress day 2 - Wednesday 7 November15.30 Afternoon teawww.terrapinn.com/2007/antibody/confp... Aanbevelingen 0 ” Quote Reageren Niet oké
aossa 7 november 2007 15:52 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 23 mrt 2025 Aanbevelingen Ontvangen: 4053 Gegeven: 3339 Aantal posts: 17.622 Re: bidden in Genk (be-limburg)Ik betwijfel het want bij Sanofi-Aventis (Lyon) hebben ze een 20K liter vat ! Aanbevelingen 0 ” Quote Reageren Niet oké
josti5 7 november 2007 17:52 auteur info josti5 Lid sinds: 23 feb 2005 Laatste bezoek: 24 mrt 2025 Aanbevelingen Ontvangen: 17886 Gegeven: 21100 Aantal posts: 34.559 'een 20K liter vat'Welk merk bier brouwen ze daarin stiekum, in afwachting van medicijn-orders? Aanbevelingen 0 ” Quote Reageren Niet oké
aossa 7 november 2007 17:54 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 23 mrt 2025 Aanbevelingen Ontvangen: 4053 Gegeven: 3339 Aantal posts: 17.622 Wijn ... veel liters franse wijn ;-)En kaas natuurlijk 'le petit Lyonais". Aanbevelingen 0 ” Quote Reageren Niet oké
josti5 7 november 2007 18:02 auteur info josti5 Lid sinds: 23 feb 2005 Laatste bezoek: 24 mrt 2025 Aanbevelingen Ontvangen: 17886 Gegeven: 21100 Aantal posts: 34.559 O, brouwen ze tegenwoordig wijn?Die schimmelkaas in een 20 KL-vat: daar kan ik mij wel iets bij voorstellen, aossa... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 7 november 2007 18:21 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:josti5 schreef:O, brouwen ze tegenwoordig wijn?Pleegzustersixwijn. Aanbevelingen 0 ” Quote Reageren Niet oké
aossa 7 november 2007 18:22 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 23 mrt 2025 Aanbevelingen Ontvangen: 4053 Gegeven: 3339 Aantal posts: 17.622 quote:josti5 schreef:O, brouwen ze tegenwoordig wijn? [/quote]Chateau Aventis, appellation Crucell grand cru classé. Grand prix des Alpes 2010.[quote=josti5]Die schimmelkaas in een 20 KL-vat: daar kan ik mij wel iets bij voorstellen, aossa...Le petit Lyonais ?Plein de proteïnes et de penicilline enrichi des anti-bodies selectionnés ! Aanbevelingen 1 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.